Retatrutide

Retatrutide is an investigational triple agonist peptide acting on GLP-1, GIP and glucagon receptors, studied extensively in metabolic research.

Retatrutide exerts its studied effects through simultaneous activation of three receptor pathways. GLP-1 receptor agonism is associated with delayed gastric emptying, increased satiety signalling to the brain, and reduced appetite. GIP receptor agonism is studied for its influence on insulin secretion in response to meals and on adipose tissue metabolism. Glucagon receptor agonism is associated with increased energy expenditure, the breakdown of stored fat (lipolysis), and hepatic glucose output. The combined engagement of all three pathways is researched for its potential to produce greater reductions in body weight and improvements in metabolic markers than targeting any single receptor alone.

Retatrutide (also known as LY3437943) is a synthetic 39-amino-acid peptide engineered to simultaneously act as an agonist at three key metabolic receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. This triple-agonist mechanism distinguishes it from single (GLP-1 only) or dual (GLP-1/GIP) incretin agonists and is of significant interest in research exploring appetite regulation, energy expenditure, and glucose homeostasis. Its extended half-life — supporting once-weekly dosing protocols in study settings — is attributed to fatty acid acylation and amino acid substitutions that slow enzymatic degradation and reduce renal clearance.

Early-phase clinical research has examined retatrutide's effects on body weight and metabolic markers, with findings suggesting substantial weight reduction in study participants. These findings are emerging and should be interpreted within the context of ongoing peer-reviewed study.